Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD 55.2 million) in a Series D+ financing round. The round was co-led by GTJA Investment and KingRay Capital, a state-owned investor focused on small and micro enterprises. Additional participants in the financing round included Guojin Group, Shanghai Guyu Nange Technology Development Center, as well as existing investors Lilly Asia Ventures and Xiamen C&D Emerging Industry Equity Investment.
Established in June 2009, Impact Therapeutics is dedicated to the development of best-in-class drugs for the treatment of cancers and other significant diseases. The company has developed a distinctive research and development platform that focuses on DNA Damage Response (DDR) as a key therapeutic target. Its pipeline is headlined by the poly-ADP ribose polymerization (PARP) inhibitor IMP4297 (senaparib), the WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064), and the PARP1 selective inhibitor (IMP1734), which is under development in collaboration with Eikon Therapeutics in the United States, along with several other DDR target inhibitors.- Flcube.com
